Suppression by interleukin 4 of activation of human blood monocytes to the tumoricidal state

Jpn J Cancer Res. 1990 Sep;81(9):936-41. doi: 10.1111/j.1349-7006.1990.tb02670.x.

Abstract

The effect of interleukin 4 (IL-4) on expression of antitumor activity of blood monocytes purified by counter-flow centrifugal elutriation from healthy donors was examined. The blood monocytes were incubated for 24 h in medium with lipopolysaccharide, interferon gamma (IFN-gamma) or desmethyl muramyl dipeptide (norMDP) or with IFN-gamma and norMDP in the presence of IL-4, and then their tumoricidal activity was assayed by measuring 125IUdR release from human melanoma (A375) cells. Irrespective of activation stimulus, addition of IL-4 to cultures of monocytes and activators resulted in dose-dependent suppression of the tumoricidal activity of monocytes against parent A375 melanoma cells and the variant cells, A375-R resistant to IL-1 and tumor necrosis factor alpha. IL-4 suppressed the early induction phase of monocyte activation. Rabbit anti-IL-4 antisera completely blocked the IL-4-mediated suppression of monocyte activation to the tumoricidal state. These findings suggest that IL-4 is important in vivo in down-regulation of anti-tumor expression of monocytes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Cytotoxicity, Immunologic / drug effects*
  • Dose-Response Relationship, Drug
  • Humans
  • Immunity, Cellular / drug effects*
  • In Vitro Techniques
  • Interleukin-1 / pharmacology
  • Interleukin-4 / pharmacology*
  • Lipopolysaccharides / pharmacology
  • Melanoma / immunology
  • Monocytes / immunology*
  • Time Factors
  • Tumor Cells, Cultured / immunology
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Interleukin-1
  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha
  • Interleukin-4